Sulfur hexafluoride microbubbles combined with serology distinguish benign and malignant ovarian tumors

Abstract

To explore the value of contrast-enhanced ultrasound with Sulfur hexafluoride microbubbles, serum carbohydrate antigen 125, carcinoembryonic antigen and human epididymis protein 4 joint inspection in the differential diagnosis of ovarian tumors. A total of 56 patients with ovarian tumors were chosen as research materials from June 2018 to October 2021. Result show 24 patients of benign tumors and 32 patients of malignant tumors were confirmed by pathological diagnosis. The rise time and time to peak values of malignant tumors were lower than those of benign tumors (p<0.001). However, peak intensity, Time intensity curve -Area under Curve and serum human epididymis protein 4, carcinoembryonic antigen, carbohydrate antigen 125 levels joint inspection in malignant tumors were higher than those in benign tumors (p < 0.001). Rise time, peak intensity and time to peak in benign and malignant ovarian tumors were 0.895 (0.802–0.999, 95% CI), 0.852 (0.804–0.916, 95% CI), 0.907 (0.829–0.925, 95% CI), respectively. Area under Curve were 0.909 (0.846–1.012, 95% CI) and serum carbohydrate antigen 125 and carcinoembryonic antigen and human epididymis protein 4 for diagnosis of benign and malignant ovarian tumors were 0.865 (0.838–0.991, 95% CI), 0.816 (0.702–0.930, 95% CI), 0.903 (0.850–1.007, 95% CI). Contrast-enhanced Ultrasound unite to serum carbohydrate antigen 125 and carcinoembryonic antigen and human epididymis protein 4, the accuracy rate 92.86% (52/56) significantly higher than Contrast-enhanced Ultrasound or serum v diagnosis benign and malignant of ovarian tumor (p<0.01, 92.86% vs. 82.14%, p<0.001, 92.86% vs. 73.21%). Conclusion Contrast-enhanced Ultrasound, carbohydrate antigen 125, carcinoembryonic antigen, human epididymis protein 4 joint inspection can improve the accuracy of early ovarian cancer.